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Summary/Abstract Interleukin-1 receptor antagonist (IL-1
RA) is an anti-inflammatory protein used clinically to treat
rheumatoid arthritis and is considered a promising candidate
therapy for stroke. Here, we sought to update the existing
systematic review and meta-analysis of IL-1 RA in models
of ischaemic stroke, published in 2009, to assess efficacy,
the range of circumstances in which efficacy has been tested
and whether the data appear to be confounded due to reported
study quality and publication bias. We included 25 sources of
data, 11 of which were additional to the original review.
Overall, IL-1 RA reduced infarct volume by 36.2 % (95 %
confidence interval 31.6–40.7, n = 76 comparisons from 1283
animals). Assessments for publication bias suggest 30 theoret-
ically missing studies which reduce efficacy to 21.9 % (17.3–
26.4). Efficacy was higher where IL-1 RA was administered
directly into the ventricles rather than peripherally, and studies
not reporting allocation concealment during the induction of
ischaemia reported larger treatment effects. The preclinical
data supporting IL-1 RA as a candidate therapy for ischaemic
stroke have improved. The reporting of measures to reduce the
risk of bias has improved substantially in this update, and
studies now include the use of animals with relevant co-
morbidities.
Keywords Systematic review .Meta-analysis . Interleukin-1
receptor antagonist . Neuroprotection . Focal cerebral
ischaemia . Experimental validity
Introduction
In recent years, systematic review and meta-analysis
have been used to provide less biased summaries of the
published evidence supporting the efficacy of candidate
drugs for stroke. The initial drivers for this effort were to
help select drugs to be tested in clinical trials [1] and to
identify important gaps in the evidence. For example, a
systematic review of the efficacy of hypothermia in ani-
mal stroke studies [2] demonstrated high headline effica-
cy, across a range of circumstances, but also illustrated
that the impact of pethidine (commonly used to manage
shivering in humans undergoing awake hypothermia) on
efficacy was not known. These findings led firstly to
targeted animal experiments exploring the impact of
pethidine [3] and then informed the design of the
EuroHYP-1 clinical trial of hypothermia for acute isch-
aemic stroke [4].
An unintended consequence of this approach has been
to establish the prevalence and impact of risks of bias in
the animal literature modelling stroke. Initial work sug-
gested a worryingly low prevalence of measures which
might reduce the risk of bias such as randomisation and
blinding and that studies which did not report such mea-
sures gave inflated estimates of treatment effects [5].
This informed the development of good practice guide-
lines for stroke research [6] and preclinical research more
generally [7, 8]. Subsequent investigation showed that,
far from being an extreme example of a highly biased
research field, in vivo stroke researchers perform at least
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as well as researchers in other neuroscience domains and
better than research published from leading UK institu-
tions [7, 9]. Further, a review of reporting quality for
publications in the journal Stroke describing in vivo re-
search reveals an apparent improvement in reporting
since the Stroke good laboratory practice (GLP) guide-
lines were published [10]. Whether this was caused by
the adoption of GLP guidelines, changes in editorial pol-
icy or other factors is not known.
In 2006, we conducted a systematic review and meta-
analysis of the effects of interleukin-1 receptor antagonist
(IL-1 RA) in animal models of ischaemic stroke [11]. This
suggested substantial efficacy but also identified a number
of potential shortcomings in the supporting animal literature:
there was significant heterogeneity between studies, the range
of conditions under which efficacy was tested was narrow,
study quality was modest when scored against established
checklists and there was evidence consistent with a substantial
publication bias. Specifically, there was a lack of evidence at
times of administration beyond 180 min, of testing in animals
with co-morbidities including hypertension or diabetes and of
testing in larger animals.
That publication led to a letter [12] to the journal editor
raising concerns about the utility of an aggregate quality
Bscore^ and about the importance attached in our review to
the demonstration of efficacy in animals with co-morbidities.
Subsequently, we have focussed in our systematic reviews on
the prevalence of individual risk of bias items rather than
calculating an overall score, but a lower efficacy in animals
with co-morbidities has been demonstrated for a number of
candidate neuroprotective drugs [5, 13].
IL-1 RA remains a promising drug for the treatment
of stroke. Subsequent to our initial publication, there
have been reports that it may modify the immune re-
sponse following severe traumatic brain injury [14] and
subarachnoid haemorrhage [15]. Clinical evaluation of
IL-1 RA for the treatment of both ischaemic and
haemorrhagic stroke is ongoing: three phase-II
randomised controlled trials have been completed, one
is ongoing and another is planned to start in 2018 [16].
The main findings in two of the completed studies sug-
gest it is well tolerated in stroke patients and there are no
safety concerns [15, 16]. To our knowledge, no phase-III
t r i a l s in ischaemic s t roke are cur rent ly under
development.
Against this background, we set out to update our existing
systematic review and meta-analysis of the efficacy of IL-1
RA in experimental stroke. As well as providing a summary of
current data for efficacy, we were also interested to see wheth-
er there had been an increase in the range of circumstances
under which efficacy has been tested and reported and wheth-
er there was an increase in the quality of reporting of studies
published since our initial review.
Methods
Search Strategy
We searched PubMed, Embase, BIOSIS and Web of Science
Core Collection for [(interleukin 1 receptor antagonist) OR
(IL-1 RA) OR (IL1RA) OR (IL1-RA) OR (Anakinra)] AND
[(stroke) OR (ischemia) OR (cerebrovascular) OR (middle
cerebral artery) OR (MCA) OR (ACA) OR (anterior cerebral
artery) OR (MCAO)] AND [(Hooijmans et al. PubMed ani-
mal filter [17]) OR (de Vries et al. Embase animal filter update
[18])] NOT [(coronary) OR (myocardial)]. We restricted the
date of publication to post-2005, and the search was complet-
ed in February 2016. Results were screened independently by
title and abstract in the SyRF screening application (http://app.
syrf.org.uk/) by up to three reviewers (minimum 0.66
agreement required for inclusion; FC, ESS and SKM). Full
texts of included articles were then screened by two reviewers
(ESS and SKM) with discrepancies resolved through
discussion.
Inclusion Criteria and Outcome Measures
We included data describing the effects of IL-1 RA compared
to a control group receiving vehicle or no treatment in whole
live animal models of focal cerebral ischaemia. We included
any mode and route of delivery of IL-1 RA (e.g. transgenic,
viral vector, peripheral) at any time point and frequency. The
primary endpoint was infarct area or volume, and secondary
endpoints were neurobehavioural scores and mortality.
Data Extraction
Two reviewers independently extracted study design, quality
and outcome data for each included comparison (ESS and
SKM). We abstracted from studies the time of first drug ad-
ministration, cumulative drug dose in the first 24 h of admin-
istration (recorded in mg/kg for peripheral and total weight
[μg] for central administration), route of drug delivery, type
(permanent/temporary/thrombotic) and method of ischaemic
occlusion, time to outcome measurement, anaesthetic used,
whether or not animals were ventilated during surgery, meth-
od of infarct measurement, publication status, and the species,
strain and sex of animals used. Where a control group served
more than one treatment group, the size of the control group
used for meta-analysis was adjusted accordingly. Where out-
comes from the same group of animals were reported at dif-
ferent time points, the last time point was extracted. Where
data were presented graphically, digital measuring software
was used, and where this was not possible, authors were
contacted seeking the original data. Where outcome data ex-
tracted digitally by the two independent reviewers differed by
<10 %, an average of the two values was taken. Data differing
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by >10 % and any other discrepancies were resolved through
discussion with a third reviewer (MRM).
Range of Evidence
We assessed the range of evidence against the updated
Stroke Therapy Academic Industry Roundtable (STAIR)
criteria [19]: (1) evidence from two or more laborato-
ries, (2) from two or more species, (3) from animals
with co-morbidities, (4) from male and female animals,
(5) from both permanent and temporary models of is-
chaemia, (6) testing at least two doses of the drug, (7)
with some doses given at least 1 h after vessel occlu-
sion, (8) testing using a feasible route of drug delivery,
(9) use of both histologic and behavioural outcomes,
(10) outcome measured at least 4 weeks after vessel
occlusion, (11) from species other than rodents, (12)
interaction studies with medications commonly used in
stroke patients and (13) use of relevant biomarker
endpoints.
Quality of Evidence
We assessed the susceptibility to bias of each publication
using the CAMARADES study quality checklist [20]
adapted to include relevant items from the updated
STAIR criteria [19]: (1) peer reviewed publication, (2)
control of temperature, (3) randomisation of group alloca-
tion, (4) blinded induction of ischaemia, (5) blinded as-
sessment of outcome, (6) avoidance of anaesthetics with
marked intrinsic neuroprotective properties, (7) use of an-
imals with co-morbidities (e.g. hypertension, diabetes), (8)
sample size calculation, (9) statement of compliance with
animal welfare requirements, (10) statement of potential
conflicts of interest, (11) physiological monitoring during
stroke induction (in addition to control of temperature, e.g.
blood pressure, gases), (12) prespecified inclusion and ex-
clusion criteria, (13) reporting of animals excluded from
analysis, (14) reporting of study funding, and (15) injury
confirmed via laser Doppler or perfusion imaging.
The range and quality of evidence items from the updated
STAIR recommendations were also extracted from the publi-
cations included in our original review.
Analysis
Our analysis plan was prespecified in a study protocol, pub-
lished online at (https://drive.google.com/file/d/0B5x-sP1A05
kgWWYtX09Re jBockE /v i ew) . Fo r i n f a r c t and
neurobehavioural outcomes, we calculated a normalised
mean difference for each comparison, and for mortality, the
odds ratio [21]. For each outcome, comparisons were
combined using random-effects modelling with a restricted
maximum likelihood (REML) estimate of between-study var-
iance. Where different measures of neurobehavioral outcome
were reported from the same cohort of animals at the same
time point, we combined these (pre-nested) comparisons
using fixed-effect meta-analysis (nesting) and used this sum-
mary estimate in the random-effects model.
We used meta-regression to investigate possible sources of
heterogeneity including components of the study quality
checklist and study design characteristics, and a significance
level of p < 0.05 was set for each test.
We tested for the presence and extent of publication bias
using funnel plots, Egger’s test and trim and fill [22, 23].
Because of concerns that meta-regression may be under-
powered in detecting important differences between studies
due to aspects of study design, we also analysed these differ-
ences using partitioning of heterogeneity as a sensitivity anal-
ysis. Sensitivity analyses were performed using DerSimonian
and Laird random-effects meta-analysis, and stratified meta-
analysis was used to investigate sources of heterogeneity.
Stratifications were considered in two domains: study design
and study quality, with each domain tested at p < 0.05 overall.
A Holm-Bonferroni adjusted critical p value was calculated to
account for the number of parameters tested within each do-
main; p < 0.003 for study design and p < 0.007 for study
quality.
Heterogeneity is described using Q (heterogeneity statis-
tic), tau2 (estimation of between-study variance), residual I2
(the percentage of the residual variation that is attributable to
between-study heterogeneity) and adjusted R2 (adj R2; the
proportion of between-study variance explained by the
covariate).
Statistical analyses were performed using Stata Statistical
Software: Release 13 (StataCorp LP, College Station, TX) or
Microsoft Access 2013.
Results
Four hundred and thirty-three publications were identified
electronically, of which 10 met our inclusion criteria.
Requests to authors for unpublished data provided one further
manuscript [24]. In total, 11 studies were added to our original
dataset. We identified one publication [25] describing studies
included in our original review as a conference abstract and
unpublished data (Clark 2005 and Clark 2006 in Banwell et al.
[11], confirmed through personal communication); these orig-
inal data are therefore excluded from the current analysis. We
identified one publication from the original review where me-
dian data were reported (an exclusion criterion in the current
review), and this study is also excluded from the current anal-
ysis [26]. Our updated dataset includes 25 studies in total
(Supp Fig. 1); study characteristics are shown in Table 1.
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The range of evidence met 11 of a possible 13 STAIR
criteria assessed. Criteria newly met in the current study are
evidence from animals with co-morbidities which include
aged, aged corpulent (a model of metabolic syndrome) and
acute infection with pneumonia or LPS, and outcome assessed
at 4 weeks post-ischaemia. The dataset now includes experi-
ments where IL-1 RA is administered up to 6 days after in-
duction of ischaemia, with 12 comparisons where administra-
tion is more than 3 h post-stroke. The number of
neurobehavioural outcomes reported increased from 1 to 33
comparisons. All studies published post-2009 administered
IL-1 RA peripherally including intravenous, intraperitoneal
and subcutaneous routes. In our original review, over half of
studies used central administration via intracerebroventricular
or intracerebral stereotactic routes. Relevant biomarker end-
points including MRI assessment of injury have been report-
ed. Although IL-1 RA has been studied in animals also treated
with tissue plasminogen activator (tPA), no in vivo interaction
studies with medications commonly used by stroke patients
such as statins, blood pressure-lowering medication and aspi-
rin were identified. Evidence is still lacking in female animals
and in species other than rodents.
Overall, the number of study quality items met is greater in
studies published post-2009 (median 11.5/15 interquartile
range [IQR] 9.75–12) than pre-2009 (median 6/15 IQR 5–7;
Table 2).
In particular, the proportion of studies reporting
randomisation, blinded induction of ischaemia, blinded assess-
ment of outcome, prespecified exclusion criteria and animal
exclusions increased substantially. Clear differences are also
evident in the proportion of studies using co-morbid animal
models and those reporting a sample size calculation (Supp
Table 1). Pre-2009, no studies reported a statement regarding
possible conflicts of interest. Post-2009, seven out of eight
studies included a statement; of these seven, one reported no
conflict while six made disclosures. Use of laser Doppler or
perfusion imaging to confirm ischaemic injury was assessed
as a quality item; however, alternative methods of confirmation
were reported in some studies: through behavioural observation
in one study and visually (microscopically) in two studies.
Infarct volume was reported in 76 comparisons from 1283
animals, neurobehavioural score in 98 (33 nested) compari-
sons from 473 animals and mortality in 10 comparisons from
227 animals. These data met our prespecified criterion for a
minimum 30 % increase in the number of independent com-
parisons required to justify an updated meta-analysis (original
dataset 44 infarct volume, 1 neurobehavioral and 2 mortality
comparisons).
Table 2 Change over time: A comparison of the data prior to the publication of our 2009 review, afterwards and with all data pooled
Pre-2009 Post-2009 Overall
No. publications 17 8 25
Animals/paper 42.5 75.1 53
Infarct volume Effect size (95 % CI) 37.5 % (30.3–44.7) 36.15 % (31.8–40.7) 36.5 % (31.6–41.3)
I2 (%) 87 72 82
# experiments 39 37 76
# animals 709 574 1283
Neurobehavioural outcome Effect size (95 % CI) 24.8 % (−8.7–58.3) 37.1 % (29.7–44.5) 35.8 % (28.2–43.5)
I2 (%) 67 58 58
# experiments 4 29 33
# animals 51 422 473
Mortality Odds ratio (95 % CI) 0.5 (0.04–5.8) 1.1 (0.5–2.8) 1.03 (0.5–2.4)
I2 – – –
# experiments 1 9 10
# animals 26 201 227
Median quality (/15) (interquartile range) 6 (5–7) 11.5 (9.8–12) 7.0 (5–7)
Random allocation to group (%) 5.9 87.5 32.0
Blinded induction of ischaemia (%) 11.8 50.0 24.0
Blinded assessment of outcome (%) 29.4 87.5 48.0
Sample size calculation (%) 0.0 37.5 12.0
Statement of potential conflict of interest (%) 0.0 87.5 28.0
Prespecified exclusion of animals (%) 11.8 62.5 28.0
Explanation of exclusions (%) 11.8 62.5 28.0
Transl. Stroke Res.
Overall, IL-1 RA reduced our primary outcome, infarct
volume, by 36.2 % (95 % confidence interval [CI] 31.6–
40.7). Administration of IL-1 RA in protein form resulted in
a 35.5 % (30.3–40.7) reduction, administration of IL-1 RA
transgenic bone marrow (BM) cells a 34.7 % (15.9–53.6)
reduction and vector transfection a 44.7 % (29.9–59.6) reduc-
tion. One comparison involved transgenic mice overexpress-
ing IL-1 RA resulting in a 43.2 % (19.1–67.3) reduction in
infarct size (Fig. 1a).
For study quality, we observed greater reduction in infarct
volume in studies that did not report that investigators were
blinded to treatment allocation during the induction of ischae-
mia (p = 0.045, tau2 = 181.6, I2 = 82.4 %, adj R2 = 3.2 %,
Fig. 2). Other potential sources of bias that did not account
for a significant proportion of heterogeneity were reporting of
randomisation to group, blinded assessment of outcome,
prespecified exclusion criteria, reasons for excluding animals,
sample size calculation and statement of potential conflict of
interest.
Due to uncertainty around the timing and effective dose
achieved in transgenic and transfection studies, analyses of
study design characteristics are restricted to 19 sources de-
scribing 65 experiments where IL-1 RA was administered in
protein form. Mode of IL-1 RA delivery (peripheral or central
delivery) is not a significant source of heterogeneity
(p = 0.412), and therefore, data were analysed together.
We observed substantial heterogeneity in this dataset
(tau2 = 231.9, I2 = 83.7 %) that was explained, in part, by
two of the variables investigated with univariate meta-regres-
sion. Firstly, for route of delivery, studies using intracerebro-
ventricular administration reported the greatest magnitude of
effect (p = 0.0003, tau2 = 121.3, I2 = 77.54 %, adj
R2 = 43.3 %). Large effects were also observed with the more
clinically relevant peripheral routes of delivery, intravenous
and subcutaneous (Fig. 3a). Secondly, dose-response relation-
ships for central (intracerebroventricular, stereotactic) and pe-
ripheral (intravenous, intraperitoneal, subcutaneous) adminis-
tration were analysed separately. Dose is a significant source
of heterogeneity in experiments where IL-1 RAwas adminis-
tered centrally (p = 0.005, tau2 = 194.8, I2 = 89.6 %, adj
R2 = 45.2 %) with larger reductions in infarct volume evident
at higher doses (Fig. 3b).
Effect sizes for data stratified by publication date (pre- or
post-2009) were similar with less statistical heterogeneity ob-
served in more recent studies: we observed a reduction in
infarct volume pre-2009 of 36.1 % (27.9–44.2), tau2 = 279.4
and I2 = 88.1 % versus 35.0 % (28.2–41.7), tau2 = 159.4 and
I2 = 74.2 % post-2009, p = 0.97.
Variables that do not contribute significantly to heteroge-
neity include the following: species and sex of animals, time
of IL-1 RA administration, whether single, multiple or contin-
uous administration was used, whether infarct volume calcu-
lation involved a correction for oedema, method of infarct
quantification, presence of co-treatments, co-morbidity stud-
ied, method of induction of ischaemia, type of ischaemia,
anaesthetic used during model induction and whether me-
chanical ventilation was used, and time of outcome assess-
ment relative to model induction.
Funnel plot asymmetry is detected with Egger’s test
(p < 0.001), suggesting the presence of publication bias
(Fig. 4a). Trim and fill analysis imputed the presence of 30
Bmissing^ experiments, with an adjusted reduction in infarct
volume of 21.9 % (17.3–26.4, Fig. 4b), 14.3 % lower than
before adjustment.
Overall, IL-1 RA improves neurobehavioural measures by
35.9 % (28.2–43.5; n = 33). No improvement was observed in
experiments where IL-1 RA transgenic BM cells were admin-
istered (n = 3, p = 0.200) (Fig. 1b). Neurobehavioural mea-
sures were categorised as tests of motor/sensory behaviours,
social interaction/anxiety/depressive behaviours or thermal
nociception. Using this categorisation, the type of
neurobehavioural test is not a significant source of heteroge-
neity (post hoc analysis; p = 0.4480). Most experiments (28/
33) tested motor/sensory outcomes, and further analyses are
restricted to these data due to the divergent biology underlying
the behaviours tested in the remaining outcomes. Only exper-
iments where IL-1 RAwas administered in protein form were
investigated for sources of heterogeneity (27 comparisons); in
all of these experiments, IL-1 RA was administered
peripherally.
Fig. 1 Effect of IL-1 RA on a
infarct volume and b
neurobehavioural outcomes.
Individual nested comparisons
grouped according to the mode of
IL-1 RA delivery and ranked
according to effect. Shaded grey
bars represent 95 % CI of global
estimate of efficacy. Vertical error
bars represent 95 % CI for
individual estimates
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For motor/sensory behaviours, there is an improvement
in outcome of 35.7 % (27.5–43.9; tau2 = 219.1,
I2 = 63.8 %, n = 27). Route of delivery accounted signifi-
cantly for this heterogeneity (p = 0.0008, tau2 = 71.8,
I2 = 32.6 %, adj R2 = 67.2 %) with the greatest improve-
ment seen with subcutaneous administration (Fig. 5a).
Greater effects are also observed in experiments that ad-
ministered multiple rather than single doses of IL-1 RA
(p = 0.018, tau2 = 133.1, I2 = 49.9 %, adj R2 =39.2 %;
Fig. 5b). Sex of the animals is a significant source of
heterogeneity (p = 0.040, tau2 = 186.6, I2 = 61.3 %, adj
R2 = 14.8 %), with no effect seen in experiments where
the sex of the animal was not reported (Fig. 5c). The
anaesthetic used during induction of ischaemia also
contributes to heterogeneity (p = 0.0023, tau2 = 62.6,
I2 = 31.7 %, adj R2 = 71.4 %). The greatest effect is seen
in studies using isoflurane while there is no effect in those
using ketamine, tribromoethanol or halothane (Fig. 5d). In
addition to the effects of anaesthesia, post-operative anal-
gesia can affect stroke outcome in rodents. Only two of
the included studies reported using an analgesic
(buprenorphine); therefore, we were unable to assess the
impact of this variable on the recorded outcomes.
We further subdivided motor/sensory behavioural mea-
sures into the more specific categories: gross neurological
score (n = 26), skilled movement task (n = 4) or sensori-
motor asymmetry test (n = 7). Post hoc analysis revealed
that type of motor/sensory measure was not a significant
source of heterogeneity (p = 0.8182). Other variables not
contributing significantly to heterogeneity are species of
animals, dose and time of IL-1 RA administration, co-
morbidity studied, method of induction of ischaemia, type
of ischaemia and time of outcome assessment relative to
model induction. Only one comparison involved a co-
treatment (tPA), and for all comparisons, it was unknown
whether mechanical ventilation was used; therefore, these
variables were not analysed.
Egger’s test suggests significant funnel plot asymmetry
(p = 0.028) (Fig. 6a). Trim and fill analysis imputed the pres-
ence of 18 Bmissing^ experiments, with improvement in
neurobehavioural outcome adjusted from 41.4 % (34.9–
47.9) down to 38.6 % (31.9–45.3) (Fig. 6b). These values
differ from the estimate of efficacy calculated using meta-
regression due to use of a moment-based rather than REML
estimate of between-study variance.
Mortality was unaffected by administration of IL-1 RA
with an odds ratio of 1.03 (0.45–2.38), n = 10, 227 animals,
Q = 2.87 and p = 0.97. Mortality was not analysed further due
to the limited data.
Fig. 3 Heterogeneity in the effect of IL-1 RA on infarct volume is in part
explained by a the route of delivery (x-axis). Vertical error bars represent
95 % CI for individual estimates. Width of each vertical bar reflects
square root of number of animals contributing to that comparison (ICV
intracerebroventricular, IV intravenous, SubCut subcutaneous, IP
intraperitoneal). b Effect of IL-1 RA dose on estimate of efficacy. Size
of points reflect the precision of each comparison (inverse of within-study
variance). Stratification by dose accounts for significant proportion of
heterogeneity observed between studies (p = 0.005)
Fig. 2 Correction of measured infarct volume for presence of blinded
induction of ischaemia. Shaded grey bar represents 95 % CI of global
estimate of efficacy. Vertical error bars represent 95 % CI for individual
estimates. Width of each vertical bar reflects square root of number of
animals contributing to that comparison
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Sensitivity Analyses
We performed stratified meta-analysis, rather than meta-regres-
sion, as a sensitivity analysis to assess the impact of study quality
anddesignon infarct volumeusinganalternative statisticalmeth-
od. For study quality, studies reporting a formal calculation of
study size reported larger treatment effects than those that did
not (Q = 13.1, df = 1, p = 0.0003) (Supp Fig. 2A). For study de-
sign, we similarly observed larger effects with intracerebroven-
tricular delivery of IL-1 RA (Q = 125.6, df = 4, p < 10−25) (Supp
Fig. 2B) and a dose response for central drug administration
(Q = 68.8, df = 2, p < 10−14) (Supp Fig. 2C). In addition, we
observed other variables to account for significant sources of het-
erogeneity.We observed the largest effects in studies using keta-
mine anaesthesia (Q = 53.2, df = 4, p < 10−10) (Supp Fig. 2D), in
thrombotic models of ischaemia (Q = 13.0, df = 2, p = 0.002)
(Supp Fig. 2E) and where ischaemia was induced via thrombin
injection(Q = 24.5,df = 3,p < 10−4) (SuppFig.2F)and instudies
which reported correcting for oedema in infarct quantification
(Q = 53.9, df = 2, p < 10−11) (Supp Fig. 2G). We observed an
inverse dose response for peripheral drug delivery (Q = 60.8,
df = 3, p < 10−12) (Supp Fig. 2H) and a significant but unclear
relation between the time of drug administration and effect
(Q = 72.3, df = 4, p < 10−14) (Supp Fig. 2I).
Fig. 5 Heterogeneity in the effect
of IL-1 RA on motor/sensory
neurobehavioural outcomes is in
part explained by a the route of
delivery, b the number of doses
administered, c the sex of the
animals used and d the
anaesthesia used during induction
of ischaemia. Shaded grey bars
represent 95 % CI of global
estimate of efficacy. Vertical error
bars represent 95 % CI for
individual estimates. Width of
each vertical bar reflects square
root of number of animals
contributing to that comparison
Fig. 4 Publication bias in infarct volume estimates assessed by a Egger’s
regression, showing regression line with 95 % CI, and b trim and fill
analysis, showing the distribution of published study outcomes (filled
circles) and imputed outcomes (unfilled circles). The solid vertical line
represents the global estimate of efficacy and the dashed line the adjusted
reduction in infarct volume when theoretically missing studies are
incorporated
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Discussion
Treatment with IL-1 RA leads to substantial improve-
ments in outcome in preclinical models of ischaemic
stroke, whether measured as reduced infarct volume or
improved neurobehavioural outcome. The range of evi-
dence supporting the administration of IL-1 RA for treat-
ment of focal ischaemic stroke has increased substantially
since our previous systematic review and meta-analysis.
Discussion with researchers in the field suggests that this
has been due to deliberate efforts to test efficacy in cir-
cumstances identified as requiring further evidence. IL-1
RA has now been tested in animals with a range of co-
morbidities, at times of administration beyond 180 min,
with outcomes assessed up to 28 days after injury and
where it is administered via a clinically plausible route.
Current phase-II trials in the UK are investigating subcu-
taneous IL-1 RA as the intravenous formulation is no
longer manufactured [16]. Our data suggests efficacy is
maintained with subcutaneous delivery. The co-
morbidities tested were corpulent rats and those with
pneumonia or treated with LPS (as a surrogate for the
response to infection). Importantly, aged animals have al-
so been tested. In our primary analysis, these co-
morbidities were not a significant source of heterogeneity
suggesting that that the efficacy of IL-1 RA is maintained
in spite of them; however, efficacy has yet to be tested in
animals with hypertension and in animals other than
rodents.
There were striking improvements in study quality
since our 2009 review; the median number of quality
checklist items scored increased from 6 of a possible
15 (IQR 5–7) to 11.5 (IQR 9.75–12), with substantial
improvements across risk of bias items. This is consistent
with the improvements observed in the reporting of
in vivo research in the journal Stroke [10] and, impor-
tantly, was only associated with a small (and not
significant) reduction in the observed efficacy. There
were other interesting changes, including a substantial
increase in the average number of animals reported in
each paper, which increased from ∼42 to ∼75. This
may reflect the increased use of power calculations.
When we planned this review, we changed the study qual-
ity and range of evidence items in response to the updated
STAIR recommendations [19]. To address concerns over the
utility of an aggregate quality Bscore^, we have instead iden-
tified seven items, identified as fundamentals of good scien-
tific enquiry [8, 19], and analysed the impact of these individ-
ually. The only study quality measure that accounted for a
significant proportion of the observed heterogeneity was allo-
cation concealment during the induction of injury, where stud-
ies which did not report allocation concealment reported sig-
nificantly larger (10 %) reductions in infarct volume. This
does not necessarily indicate that other measures to reduce
the risk of bias do not have an effect, and it may be that the
increase in the range of conditions tested and the observed
increase in quality may be masking the identification of im-
portant determinants of outcome. Indeed, only two further
variables had a significant impact on efficacy using meta-re-
gression: we saw substantially larger effects and a robust dose-
response relationship where IL-1 RA was administered cen-
trally. A sensitivity analysis using partitioning of heterogene-
ity did not add substantially to our understanding.
Importantly, while the number of research teams contribut-
ing data remains somewhat limited, one included study did
report data from a multilaboratory study involving eight ex-
periments over five European centres [27].
Systematic review and meta-analysis of data from
animal studies are increasingly performed and can serve
a number of purposes. For instance, reviews of animal
studies modelling stroke testing the efficacy of hypo-
thermia [2] and antidepressants [28] have helped to in-
form the design of clinical trials including EuroHyp [4]
and FOCUS [29] which are now recruiting. They can
Fig. 6 Publication bias in neurobehavioural outcome estimates assessed
by a Egger’s regression, showing regression line with 95%CI, and b trim
and fill analysis, showing the distribution of published study outcomes
(filled circles) and imputed outcomes (unfilled circles). The solid vertical
line represents the global estimate of efficacy and the dashed line the
adjusted reduction in infarct volume when theoretically missing studies
are incorporated
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also draw attention to gaps in the quality and range of
literature describing the efficacy of a particular drug that
might highlight the need for further preclinical research
prior to clinical trials. Of 30 instruments for assessing
risk of bias of animal research, the most commonly
modelled disease was stroke (9 instruments) [30],
highlighting a desire to improve the translational poten-
tial of preclinical stroke research. Of ongoing interest in
systematic review is the impact of individual assessment
items on estimates of efficacy in large datasets, which
will provide greater validity and reliability in risk of
bias assessments of stroke data. Here, we have demon-
strated the impact of our initial review of IL-1 RA on
subsequent preclinical research and show that the effi-
cacy original ly observed has been maintained.
Systematic reviews may also have an important 3Rs
impact; our earlier systematic review and meta-analysis
has allowed more targeted use of animals in this field
and we now have a more complete picture of the use-
fulness of IL-1 RA for treating ischaemic stroke. The
current review supports the continued investigation of
IL-1 RA and identifies where efficacy remains to be
verified in animals.
The limitations of this review include that our data were
insufficient to perform multivariate regression using all vari-
ables of interest. This would have provided valuable informa-
tion on the correlation of variables. Our analyses were
prespecified, and it is possible that variables other than those
investigated contributed to heterogeneity in the datasets.
Additionally, as with all systematic reviews, we could only
assess the impact of variables as they were reported. Not
reporting blinded assessment of outcome, for example, does
not necessarily mean researchers were not blinded.
To our knowledge, this is the first update to a pre-
clinical systematic review where the changes over time
in a field can be charted and the possible impacts of
systematic review on the directions taken by researchers
investigated. We understand from leading IL-1 RA in-
vestigators in this field that our first systematic review
had a substantial, and useful, effect on their research
directions. While our 2009 review was considered over-
ly critical in many respects, the objective appraisal of
range of evidence for IL-1 RA in cerebral ischaemia led
researchers to address many of the evidence gaps and
contributed to substantial improvements in the reporting
of measures to reduce the risk of bias. In spite of the
evidence for publication bias in the primary outcome
measure, substantial efficacy remains, and this has been
confirmed in a multicentre animal study. The major
standout remaining evidence required is efficacy in hy-
pertensive animals and in female animals. On the basis
of evidence currently available, IL-1 RA is an attractive
candidate drug for clinical trial.
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